Innate Pharma's quarterly cash, cash equivalents, marketable securities
declined
from Dec. 2024 ($84.58 Mil) to Jun. 2025 ($69.24 Mil) but then
stayed the same
from Jun. 2025 ($69.24 Mil) to Dec. 2025 ($40.18 Mil).
Innate Pharma's annual cash, cash equivalents, marketable securities
declined
from Dec. 2023 ($100.82 Mil) to Dec. 2024 ($84.58 Mil) and
declined
from Dec. 2024 ($84.58 Mil) to Dec. 2025 ($40.18 Mil).
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Innate Pharma Cash, Cash Equivalents, Marketable Securities Related Terms
Innate Pharma Cash, Cash Equivalents, Marketable Securities Historical Data
* Premium members only.
The historical data trend for Innate Pharma's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
What does a Cash, Cash Equivalents, Marketable Securities of $40.18 Mil mean?
Innate Pharma (IPHA) has a Cash, Cash Equivalents, Marketable Securities of $40.18 Mil as of Dec. 2025. The total cash, cash equivalents and marketable securities a company has on hand. View historical data on Innate Pharma and its competitors.
Is Innate Pharma's Cash, Cash Equivalents, Marketable Securities too high?
Innate Pharma's current Cash, Cash Equivalents, Marketable Securities is $40.18 Mil. Overall, Innate Pharma has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Innate Pharma's Cash, Cash Equivalents, Marketable Securities compare to VRTX and REGN?
Innate Pharma's Cash, Cash Equivalents, Marketable Securities of $40.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash, Cash Equivalents, Marketable Securities for a Biotechnology company?
A good Cash, Cash Equivalents, Marketable Securities depends on the Biotechnology industry context. However, Cash, Cash Equivalents, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash, Cash Equivalents, Marketable Securities mean?
A high Cash, Cash Equivalents, Marketable Securities can signal that a stock is expensive relative to its fundamentals. The total cash, cash equivalents and marketable securities a company has on hand. View historical data on Innate Pharma and its competitors. Innate Pharma's current Cash, Cash Equivalents, Marketable Securities is $40.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innate Pharma stock overvalued right now?
Based on GuruFocus' analysis, Innate Pharma (IPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.93 — trading 1103.1% above its estimated fair value. The current Cash, Cash Equivalents, Marketable Securities is $40.18 Mil. Innate Pharma's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash, Cash Equivalents, Marketable Securities calculated?
Cash, Cash Equivalents, Marketable Securities is calculated from a company's financial statements. For Innate Pharma (IPHA), the current Cash, Cash Equivalents, Marketable Securities is $40.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innate Pharma (IPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued.
The current stock price of $1.93 is trading 1103.1% above its estimated GF Value™ of $0.16.
GuruFocus considers Innate Pharma to be Significantly Overvalued.
Key valuation signals for IPHA:
Cash, Cash Equivalents, Marketable Securities: $40.18 Mil
GF Value™: $0.16 vs. price of $1.93 (1103.1% above fair value)
No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score
Get the complete analysis for IPHA
Cash, Cash Equivalents, Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPHA has been successfully added to your 
